KM
Therapeutic Areas
Biocon Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Semglee (Insulin Glargine) | Diabetes | Approved |
| Ogivri (Trastuzumab) | Breast Cancer | Approved |
| Fulphila (Pegfilgrastim) | Neutropenia | Approved |
| Hulio (Adalimumab) | Autoimmune Diseases | Approved |
| Bmab (Bevacizumab) | Cancer | Approved |
| Insulin Aspart | Diabetes | Phase 3 |
| Tocilizumab | Rheumatoid Arthritis | Filed |
| Denosumab | Osteoporosis | Phase 3 |
Leadership Team at Biocon
SM
Siddharth Mittal
CEO and Managing Director
IS
Indranil Sen
Chief Financial Officer
ST
Shreehas Tambe
CEO, Biocon Biologics
KU
Kedar Upadhye
Global Head, Clinical Development and Medical Affairs
AC
Arun Chandavarkar
COO and Joint MD
RW
Russell Walls
Independent Director
MD
Meleveetil Damodaran
Independent Director
BK
Bobby Kanubhai Parikh
Independent Director
NC
Nirav Chandra Merchant
Independent Director
MH
Mary Harney
Independent Director